Search research articles
Contact Us
Filters
Showing results (641-650 of 708) with videos related to
Page
of 71
Sort By:
Current Molecular Medicine
|
March 4, 2015
Clinical utility of neuronal cells directly converted from fibroblasts of patients for neuropsychiatric disorders: studies of lysosomal storage diseases and channelopathy
S Kano, M Yuan, R A Cardarelli, et al.
Microbiome
|
January 19, 2020
Warming-induced permafrost thaw exacerbates tundra soil carbon decomposition mediated by microbial community
Jiajie Feng, Cong Wang, Jiesi Lei, et al.
Nature Medicine
|
November 21, 2017
CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy
Terry J Fry, Nirali N Shah, Rimas J Orentas, et al.
Leukemia & Lymphoma
|
March 3, 2021
Risk-adapted, ofatumumab-based chemoimmunotherapy and consolidation in treatment-naïve chronic lymphocytic leukemia: a phase 2 study
Sanjal Desai, Clifton Mo, Erika M Gaglione, et al.
Blood
|
February 28, 2018
Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study
Inhye E Ahn, Mohammed Z H Farooqui, Xin Tian, et al.
Journal for Immunotherapy of Cancer
|
June 5, 2026
CD19/CD22 bivalent CAR T cells in children, adolescents and young adults with B-ALL: final phase 1 trial results
Sara K Silbert, Flavia Gava, Bonnie Yates, et al.
Leukemia
|
June 26, 2026
Plasticity under pressure: biology and detection of lineage switch in acute leukemia
Alexandra E Kovach, Yang-Yang Ding, Adam J Lamble, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy
|
December 29, 2023
Rapid anti-myeloma activity by T cells expressing an anti-BCMA CAR with a human heavy-chain-only antigen-binding domain
Lekha Mikkilineni, Danielle A Natrakul, Norris Lam, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 12, 2021
Blinatumomab Nonresponse and High-Disease Burden Are Associated With Inferior Outcomes After CD19-CAR for B-ALL
Regina M Myers, Agne Taraseviciute, Seth M Steinberg, et al.
Blood Advances
|
April 28, 2022
Preinfusion factors impacting relapse immunophenotype following CD19 CAR T cells
Adam J Lamble, Regina M Myers, Agne Taraseviciute, et al.
Page
of 71
Search research articles
Search
Showing results (641-650 of 708) with videos related to
Sort By:
Page
of 71
Current Molecular Medicine
|
March 4, 2015
Clinical utility of neuronal cells directly converted from fibroblasts of patients for neuropsychiatric disorders: studies of lysosomal storage diseases and channelopathy
S Kano, M Yuan, R A Cardarelli, et al.
Microbiome
|
January 19, 2020
Warming-induced permafrost thaw exacerbates tundra soil carbon decomposition mediated by microbial community
Jiajie Feng, Cong Wang, Jiesi Lei, et al.
Nature Medicine
|
November 21, 2017
CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy
Terry J Fry, Nirali N Shah, Rimas J Orentas, et al.
Leukemia & Lymphoma
|
March 3, 2021
Risk-adapted, ofatumumab-based chemoimmunotherapy and consolidation in treatment-naïve chronic lymphocytic leukemia: a phase 2 study
Sanjal Desai, Clifton Mo, Erika M Gaglione, et al.
Blood
|
February 28, 2018
Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study
Inhye E Ahn, Mohammed Z H Farooqui, Xin Tian, et al.
Journal for Immunotherapy of Cancer
|
June 5, 2026
CD19/CD22 bivalent CAR T cells in children, adolescents and young adults with B-ALL: final phase 1 trial results
Sara K Silbert, Flavia Gava, Bonnie Yates, et al.
Leukemia
|
June 26, 2026
Plasticity under pressure: biology and detection of lineage switch in acute leukemia
Alexandra E Kovach, Yang-Yang Ding, Adam J Lamble, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy
|
December 29, 2023
Rapid anti-myeloma activity by T cells expressing an anti-BCMA CAR with a human heavy-chain-only antigen-binding domain
Lekha Mikkilineni, Danielle A Natrakul, Norris Lam, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 12, 2021
Blinatumomab Nonresponse and High-Disease Burden Are Associated With Inferior Outcomes After CD19-CAR for B-ALL
Regina M Myers, Agne Taraseviciute, Seth M Steinberg, et al.
Blood Advances
|
April 28, 2022
Preinfusion factors impacting relapse immunophenotype following CD19 CAR T cells
Adam J Lamble, Regina M Myers, Agne Taraseviciute, et al.
Page
of 71